From January 1, 2022 to March 31, 2022, the company has repurchased 9,156,916 shares, representing 0.83% for CNY 222.43 million. With this, the company has completed the repurchase of 21,227,523 shares, representing 1.92% for CNY 550.21 million under the buyback announced on July 26, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.92 CNY | +0.31% | +2.11% | -2.27% |
23/04 | Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income | MT |
23/04 | Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.27% | 4.81B | |
+19.98% | 43.48B | |
+20.67% | 22.65B | |
+14.56% | 14.73B | |
+44.72% | 12.04B | |
-8.37% | 7.08B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+11.90% | 5.47B | |
+6.69% | 4.72B |
- Stock Market
- Equities
- 002294 Stock
- News Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on July 26, 2021.